Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid...(sion 2) cartilagedestruction and 3) pann...),Health

Date:9/5/2008

sion, 2) cartilage destruction, and 3) pannus formation were observed. These are some of the same parameters that can be seen in rheumatoid arthritis damage in humans. CEL-2000 was as good as, and possibly superior to, Enbrel in slowing further disease progression as evaluated by these histological parameters and by footpad swelling as well as externally visible joint damage.

"It is very exciting to see the reduction of severe rheumatoid arthritis damage in these animals through a simple vaccination," said Dr. Zimmerman. "I hope that CEL-2000 will some day be used to lessen the damage caused by rheumatoid arthritis in patients."

CEL-2000 may offer a number of potential advantages over the existing rheumatoid arthritis treatments. Data collected in the animal studies conducted with CEL-2000 demonstrate it is effective with fewer and smaller doses. It is also potentially less toxic and more disease specific therapy. Finally, CEL-2000 could also be useful for patients who are not able to take or who may be unresponsive to existing products.

Rheumatoid arthritis treatments comprise a $13 billion market. Enbrel, a leading rheumatoid arthritis treatment sold by Amgen and Wyeth, reported US sales in 2007 of about $3.2 billion. Enbrel is a soluble recombinant protein of a human TNF-alpha receptor linked to human IgG Fc. In some cases, human or humanized monoclonal antibodies to TNF-alpha have also been used for therapy in rheumatoid arthritis. These therapies remove or inactivate TNF-alpha, a natural human cytokine required in many immune functions for normal defenses.

CEL-SCI's rheumatoid arthritis vaccine CEL-2000 was discovered as part of work with the Company's ongoing research and development activities with its L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology. L.E.A.P.S.(TM) is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an an
'/>"/>

SOURCE CEL-SCI Corporation Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
3. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
4. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
5. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
6. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
7. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
8. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
9. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
10. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
11. New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly